Xiaoxin Mu

机构：Chinese Academy of Medical Sciences & Peking Union Medical College, Jiangsu Province Hospital, Nanjing Medical University · ORCID：0000-0003-2573-3879

发表论文 26 篇 · 总被引 684 次 · h-index 13

代表论文

• Gut microbiota–derived short‐chain fatty acids regulate group 3 innate lymphoid cells in HCC (2022 · Hepatology · 被引 191)
• Hepatic stellate cell activation and senescence induced by intrahepatic microbiota disturbances drive progression of liver cirrhosis toward hepatocellular carcinoma (2022 · Journal for ImmunoTherapy of Cancer · 被引 110)
• MiR-135a functions as a tumor suppressor in epithelial ovarian cancer and regulates HOXA10 expression (2014 · Cellular Signalling · 被引 105)
• Effect of Tumor Size on Cancer-Specific Survival in Small Hepatocellular Carcinoma (2015 · Mayo Clinic Proceedings · 被引 45)
• Identification of TAF1 , HNF4A , and CALM2 as potential therapeutic target genes for liver fibrosis (2018 · Journal of Cellular Physiology · 被引 32)
• Long Non-coding RNA SNHG17 Upregulates RFX1 by Sponging miR-3180-3p and Promotes Cellular Function in Hepatocellular Carcinoma (2021 · Frontiers in Genetics · 被引 29)